Alfuzosin

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H27N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 90347YTW5F, chemically known as 2-furancarboxamide, n-(3-((4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro- but generally known as alfuzosin, which bears US NIH Compound Identifier 2092. Alfuzosin comes in base and hydrochloride forms. European Medicines Agency schedules Alfuzosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05319MIG. The term ALFUZOSIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). World Health Organization schedules alfuzosin in its Anatomical Therapeutic Chemical (ATC) Classification. ALFUZOSIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alfuzosin under HS 29349990 and SITC 51579. As of Q4 2014, ALFUZOSIN remains the US FDA Preferred Term for this commodity. Alfuzosin bears US NLM identifiers UMLS ID C0051150 and NCI Concept Code C61627. SMILES: O1C(CCC1)C(=O)NCCCN(C1NC2C(C(N1)N)CC(OC)C(OC)C2)C.